Chronic Idiopathic Urticaria (DBCOND0034097)

Identifiers

Synonyms

Chronic Urticaria, Idiopathic / Chronic, uncomplicated Idiopathic urticaria / Uncomplicated Chronic idiopathic urticaria / Chronic idiopathic urticaria / Chronic Spontaneous Urticaria / Chronic idiopathic urticaria (disorder)

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Cetirizine	A selective Histamine-1 antagonist drug used in allergic rhinitis and chronic urticaria.	Histamine H1 receptortarget ATP-dependent translocase ABCB1transporter
Desloratadine	A second generation tricyclic antihistamine used to treat seasonal and non seasonal allergic rhinitis, pruritus, and urticaria.	Histamine H1 receptortarget ATP-dependent translocase ABCB1transporter
Fexofenadine	A selective H1-antagonist for the symptomatic treatment of seasonal allergic rhinitis and chronic idiopathic urticaria.	Histamine H1 receptortarget ATP-dependent translocase ABCB1transporter Solute carrier organic anion transporter family member 2B1transporter Solute carrier organic anion transporter family member 1A2transporter Solute carrier organic anion transporter family member 1B1transporter Solute carrier organic anion transporter family member 1B3transporter Organic anion transporter 3transporter ATP-binding cassette sub-family C member 2transporter ATP-binding cassette sub-family C member 3transporter Albumincarrier alpha1-acid glycoproteincarrier
Levocetirizine	An H1-receptor antagonist used to treat symptoms associated with chronic allergic rhinitis and uncomplicated cases of chronic idiopathic urticaria.	Histamine H1 receptortarget Solute carrier family 22 member 11transporter Cytochrome P450 3A4enzyme Albumincarrier
Omalizumab	A monoclonal anti-immunoglobulin E (IgE) antibody used to treat asthma, chronic idiopathic urticaria, chronic rhinosinusitis with nasal polyps, and IgE-mediated food allergy.	Immunoglobulin heavy constant epsilontarget

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05916937	Extending Omalizumab Treatment Intervals in Patients with Chronic Spontaneous Urticaria	Omalizumab	treatment	4	recruiting
NCT06555328	Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa	No drug interventions	treatment	2	not_yet_recruiting
NCT04774315	Molecular Endotypes of Chronic Idiopathic Urticaria	Omalizumab	diagnostic	4	active_not_recruiting
NCT05936567	Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria	Povorcitinib	treatment	2	recruiting
NCT01599637	Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment	No drug interventions	basic_science	2	completed
NCT01287117	A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment	Omalizumab	treatment	3	completed
NCT03858634	A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases	Vixarelimab	treatment	2	completed
NCT03183024	Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody	Benralizumab	treatment	4	completed
NCT01803763	Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients	Omalizumab	basic_science	2 / 3	completed
NCT01264939	A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists	Diphenhydramine Omalizumab	treatment	3	completed
NCT03406325	Mast Cell Activation Test in Allergic Disease	No drug interventions	Not Available	Not Available	completed
NCT01030120	Etanercept for the Treatment of Chronic Urticaria	Etanercept	treatment	2 / 3	withdrawn
NCT00757562	Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives, Who Are Poor Metabolizers of Desloratadine (Study P02994)	Desloratadine	treatment	3	completed
NCT00536380	Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849)	Desloratadine	treatment	4	completed
NCT04175704	Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontaneous Urticaria	No drug interventions	treatment	1	not_yet_recruiting
NCT00264303	CUTE (Chronic Urticaria Treatment Evaluation)	Desloratadine Levocetirizine	treatment	4	completed
NCT02031679	Efficacy and Safety of Chemoattractant Receptor-homologous Molecule Expressed on T Helper Type 2 (CRTh2) Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines	No drug interventions	treatment	2	completed
NCT00783354	A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147)	Desloratadine	treatment	4	completed
NCT02166151	Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria	Omalizumab	treatment	3	unknown_status
NCT00866788	A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)	Diphenhydramine Omalizumab	treatment	2	completed
NCT00346606	The Efficacy and Safety of Desloratadine With Levocetirizine in Treatment of Chronic Idiopathic Urticaria	Levocetirizine	treatment	4	unknown_status
NCT05774639	Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria	Omalizumab	treatment	3	recruiting
NCT02814630	Three-month, Single-center Study to Identify Biomarkers/Response to Xolair Therapy in Chronic Idiopathic Urticaria	Omalizumab	other	Not Available	completed
NCT01292473	A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)	Omalizumab	treatment	3	completed
NCT01635127	Efficacy Study of Canakinumab to Treat Urticaria	Canakinumab	treatment	2	unknown_status